Krystal Biotech (KRYS) 10% Owner Suma Krishnan Sells Shares

What Happened

• Suma Krishnan (reported as a 10% owner) sold a total of 25,000 Krystal Biotech (KRYS) shares in multiple open‑market transactions on September 4, 2026. The lots ranged in price from about $354.54 to $366.56, generating proceeds of $8,982,986 (≈ $9.0M). Each reported sale is coded as an S (sale).

Key Details

• Transaction date: 2026-09-04 (all sales executed that day).
• Shares sold: 25,000 total across 13 lots (individual lot sizes and prices listed in the filing).
• Proceeds: $8,982,986 total.
• Price range (reported per lot): approx. $354.54 – $366.56; several lots were executed as multiple trades and reported as weighted average prices (see filing footnotes F3–F15).
• Notable footnotes: sales were pursuant to a Rule 10b5‑1 trading plan adopted on Sep 4, 2025 that has now reached its maximum shares and terminated (F2); several lots reflect multi‑trade weighted average prices and the filer offers to provide per‑trade details on request (F3–F15). The filer disclaims beneficial ownership of shares directly owned by her spouse; spouse’s transactions are reported separately (F1). Ownership held in various trusts is described (F16–F18).
• Shares owned after transaction: not disclosed in this Form 4.
• Filing timeliness: reported on Sep 4, 2026 (same day), so the filing appears timely.

Context

• These are sales (not purchases or option exercises) and were executed under a prearranged Rule 10b5‑1 plan—commonly used to sell shares on a scheduled basis and not necessarily an indication of current sentiment. As a 10% owner, Ms. Krishnan is a large shareholder rather than identified here as a company executive; trust and spousal holdings are disclosed separately.